298 related articles for article (PubMed ID: 18178863)
1. Low-dose targeted complement inhibition protects against renal disease and other manifestations of autoimmune disease in MRL/lpr mice.
Atkinson C; Qiao F; Song H; Gilkeson GS; Tomlinson S
J Immunol; 2008 Jan; 180(2):1231-8. PubMed ID: 18178863
[TBL] [Abstract][Full Text] [Related]
2. The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice.
Sekine H; Kinser TT; Qiao F; Martinez E; Paulling E; Ruiz P; Gilkeson GS; Tomlinson S
Arthritis Rheum; 2011 Apr; 63(4):1076-85. PubMed ID: 21452327
[TBL] [Abstract][Full Text] [Related]
3. Administration of a soluble recombinant complement C3 inhibitor protects against renal disease in MRL/lpr mice.
Bao L; Haas M; Kraus DM; Hack BK; Rakstang JK; Holers VM; Quigg RJ
J Am Soc Nephrol; 2003 Mar; 14(3):670-9. PubMed ID: 12595503
[TBL] [Abstract][Full Text] [Related]
4. Complement component C3 is not required for full expression of immune complex glomerulonephritis in MRL/lpr mice.
Sekine H; Reilly CM; Molano ID; Garnier G; Circolo A; Ruiz P; Holers VM; Boackle SA; Gilkeson GS
J Immunol; 2001 May; 166(10):6444-51. PubMed ID: 11342671
[TBL] [Abstract][Full Text] [Related]
5. Transgenic expression of a soluble complement inhibitor protects against renal disease and promotes survival in MRL/lpr mice.
Bao L; Haas M; Boackle SA; Kraus DM; Cunningham PN; Park P; Alexander JJ; Anderson RK; Culhane K; Holers VM; Quigg RJ
J Immunol; 2002 Apr; 168(7):3601-7. PubMed ID: 11907125
[TBL] [Abstract][Full Text] [Related]
6. The dual role of complement in the progression of renal disease in NZB/W F(1) mice and alternative pathway inhibition.
Sekine H; Ruiz P; Gilkeson GS; Tomlinson S
Mol Immunol; 2011 Oct; 49(1-2):317-23. PubMed ID: 22000720
[TBL] [Abstract][Full Text] [Related]
7. Excessive matrix accumulation in the kidneys of MRL/lpr lupus mice is dependent on complement activation.
Bao L; Zhou J; Holers VM; Quigg RJ
J Am Soc Nephrol; 2003 Oct; 14(10):2516-25. PubMed ID: 14514729
[TBL] [Abstract][Full Text] [Related]
8. A complement C3 inhibitor specifically targeted to sites of complement activation effectively ameliorates collagen-induced arthritis in DBA/1J mice.
Song H; Qiao F; Atkinson C; Holers VM; Tomlinson S
J Immunol; 2007 Dec; 179(11):7860-7. PubMed ID: 18025232
[TBL] [Abstract][Full Text] [Related]
9. Effects of complement factor D deficiency on the renal disease of MRL/lpr mice.
Elliott MK; Jarmi T; Ruiz P; Xu Y; Holers VM; Gilkeson GS
Kidney Int; 2004 Jan; 65(1):129-38. PubMed ID: 14675043
[TBL] [Abstract][Full Text] [Related]
10. Modulation of renal disease in MRL/lpr mice genetically deficient in the alternative complement pathway factor B.
Watanabe H; Garnier G; Circolo A; Wetsel RA; Ruiz P; Holers VM; Boackle SA; Colten HR; Gilkeson GS
J Immunol; 2000 Jan; 164(2):786-94. PubMed ID: 10623824
[TBL] [Abstract][Full Text] [Related]
11. Essential Roles for Mannose-Binding Lectin-Associated Serine Protease-1/3 in the Development of Lupus-Like Glomerulonephritis in MRL/
Machida T; Sakamoto N; Ishida Y; Takahashi M; Fujita T; Sekine H
Front Immunol; 2018; 9():1191. PubMed ID: 29892304
[TBL] [Abstract][Full Text] [Related]
12. Fc receptor-independent development of autoimmune glomerulonephritis in lupus-prone MRL/lpr mice.
Matsumoto K; Watanabe N; Akikusa B; Kurasawa K; Matsumura R; Saito Y; Iwamoto I; Saito T
Arthritis Rheum; 2003 Feb; 48(2):486-94. PubMed ID: 12571859
[TBL] [Abstract][Full Text] [Related]
13. Complement receptor of the immunoglobulin superfamily reduces murine lupus nephritis and cutaneous disease.
Lieberman LA; Mizui M; Nalbandian A; Bossé R; Crispín JC; Tsokos GC
Clin Immunol; 2015 Oct; 160(2):286-91. PubMed ID: 25988858
[TBL] [Abstract][Full Text] [Related]
14. Negative role of colony-stimulating factor-1 in macrophage, T cell, and B cell mediated autoimmune disease in MRL-Fas(lpr) mice.
Lenda DM; Stanley ER; Kelley VR
J Immunol; 2004 Oct; 173(7):4744-54. PubMed ID: 15383612
[TBL] [Abstract][Full Text] [Related]
15. Activated protein C attenuates systemic lupus erythematosus and lupus nephritis in MRL-Fas(lpr) mice.
Lichtnekert J; Rupanagudi KV; Kulkarni OP; Darisipudi MN; Allam R; Anders HJ
J Immunol; 2011 Sep; 187(6):3413-21. PubMed ID: 21849682
[TBL] [Abstract][Full Text] [Related]
16. IL-12 deficiency in MRL-Fas(lpr) mice delays nephritis and intrarenal IFN-gamma expression, and diminishes systemic pathology.
Kikawada E; Lenda DM; Kelley VR
J Immunol; 2003 Apr; 170(7):3915-25. PubMed ID: 12646661
[TBL] [Abstract][Full Text] [Related]
17. Piperlongumine alleviates lupus nephritis in MRL-Fas(lpr) mice by regulating the frequency of Th17 and regulatory T cells.
Yao L; Chen HP; Ma Q
Immunol Lett; 2014 Sep; 161(1):76-80. PubMed ID: 24837470
[TBL] [Abstract][Full Text] [Related]
18. Icariin alleviates murine lupus nephritis via inhibiting NF-κB activation pathway and NLRP3 inflammasome.
Su B; Ye H; You X; Ni H; Chen X; Li L
Life Sci; 2018 Sep; 208():26-32. PubMed ID: 30146016
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the alternative complement pathway by antisense oligonucleotides targeting complement factor B improves lupus nephritis in mice.
Grossman TR; Hettrick LA; Johnson RB; Hung G; Peralta R; Watt A; Henry SP; Adamson P; Monia BP; McCaleb ML
Immunobiology; 2016 Jun; 221(6):701-8. PubMed ID: 26307001
[TBL] [Abstract][Full Text] [Related]
20. Complement factor B inhibitor LNP023 improves lupus nephritis in MRL/lpr mice.
Chen K; Deng Y; Shang S; Tang L; Li Q; Bai X; Chen X
Biomed Pharmacother; 2022 Sep; 153():113433. PubMed ID: 36076550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
